Welcome to MyStrategist

Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today

Subscribe Browse

Latest from Market Pathways

Global Medical Device Regulatory, Reimbursement, and Policy Review

Regulatory & Reimbursement

Pathways Picks May 24: EPA-FDA Chatter, Review Redesign, EU Dashboard, and More

In this week’s roundup: House Energy and Commerce Republicans are seeking a joint briefing from EPA and FDA on the impact of recently proposed ethylene oxide restrictions on medical device supply; CDRH is eyeing a premarket “redesign” in the name of simplicity, and has opened up online progress tracking of Pre-Submissions; the EU is preparing to launch a periodically updated dashboard on notified body performance; and updates from CMS, the Federal Trade Commission, UK NICE, and more.

Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways

Start Trial

Latest from MedTech Strategist

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.


Proprio: Illuminating Machine-Guided Spinal Surgery

Robotic technologies have historically been used in limited capacities in spinal surgery, though they have demonstrated utility in navigating the placement of implants as imaging capabilities improved. Now, Proprio’s solution, Paradigm, will offer surgeons 3D visualization of the operating field with real-time feedback and full data connectivity, bringing the spinal field into the digital age.

Don't Just Advertise... Strategize!

Advertise with MedTech Strategist and be seen by medtech's most influential executives.

Learn More

Latest from Community Blog

MedTech Strategist's free Community Blog explores the passion behind the people, technologies, and companies impacting the global device space.

Investors & Dealmaking

The Disappointing History of Spine M&A

Wall Street has not reacted positively to the news of the proposed Globus-NuVasive merger. Both companies must convince reluctant shareholders of the value proposition, given the history of disappointing deals in spine. Excerpted from our recent feature article.

Our strategic publications provide actionable intelligence to support each member of your organization. Check to see if your company has access.

Learn More